Clinical trial for Chemotherapy-Induced Peripheral Neuropathy
Official title A Virtually Delivered Diet Intervention (LASO-3) for the Improvement of Chemotherapy-Induced Peripheral Neuropathy in Cancer Survivors Post-treatment
ClinicalTrials.gov ID: NCT07365007
What this study is testing
- What it's testing
- The study tests whether a diet that limits added sugar, boosts fiber, and adds omega‑3 foods can reduce nerve pain caused by chemotherapy. It looks at changes in numbness, tingling, or pain in the hands and feet.
- Who it's for
- Cancer survivors who have finished treatment and are experiencing chemotherapy‑induced peripheral neuropathy.
- What's involved
- Participants will have online nutrition education sessions with a registered dietitian. The dietitian will give personalized advice to meet the three dietary goals and will check in during the program.
- Time commitment
- The program lasts several weeks, with a series of virtual visits and follow‑up assessments to track nerve pain symptoms.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- 18 years or older
- At least three months since last receiving neurotoxic chemotherapy
- Self-report moderate (≥ 2/4) numbness and tingling on the Patient Reported Outcomes-Common Terminology Criteria for Adverse Events (PRO-CTCAE™)...
- Speak/read English
- Have access to the internet
You likely can't join if
- Pre-existing peripheral neuropathy from any cause
- Plan to begin a new prescription of duloxetine (i.e., first-line treatment for CIPN pain) during the study period
- Are enrolled in symptom management trials that may alter CIPN severity
- High grade inflammatory disease such as lupus, Crohn's disease, or rheumatoid arthritis
- Routine nonsteroidal anti-inflammatory drug (NSAID) or steroid supplementation
- Consuming an average three or more servings of fish per week and/or consuming fish oil capsules containing eicosapentaenoic acid (EPA)+...
See the full eligibility criteria
- 18 years or older
- At least three months since last receiving neurotoxic chemotherapy
- Self-report moderate (≥ 2/4) numbness and tingling on the Patient Reported Outcomes-Common Terminology Criteria for Adverse Events (PRO-CTCAE™) Numbness and Tingling Severity Item in the last week
- Speak/read English
- Have access to the internet
- Pre-existing peripheral neuropathy from any cause
- Plan to begin a new prescription of duloxetine (i.e., first-line treatment for CIPN pain) during the study period
- Are enrolled in symptom management trials that may alter CIPN severity
- High grade inflammatory disease such as lupus, Crohn's disease, or rheumatoid arthritis
- Routine nonsteroidal anti-inflammatory drug (NSAID) or steroid supplementation
- Consuming an average three or more servings of fish per week and/or consuming fish oil capsules containing eicosapentaenoic acid (EPA)+ docosahexaenoic acid (DHA) daily or consuming flax oil capsules daily
- Consuming an average of less than 5 servings of sweets, candy bars, chocolate, doughnuts, cookies, cakes, pie, brownies, ice cream, pastries, or sugar sweetened beverages (e.g., soda or coffee/tea) per week
The study team makes the final eligibility decision.
Where it is enrolling
- Ann Arbor, Michigan, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Ann Arbor, Michigan, United States. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.